Enabling precision medicin for
chronic infections
Need
After antiretroviral treatment against HIV is initiated, the virus disappears while leaving the infected cells intact in a chronic reservoir. This reservoir determines the need for medication. Today, the reservoir cannot be monitored. This hampers development of new drugs and prevents optimal drug usage.
Solution
We will provide a service (later a kit) to precisely and sensitively determine the integration of a foreign DNA sequence in a genome. This can be used for 1) research and drug development or 2) diagnostics and later 3) precision medicine.
“Through knowledge we reduce HIV-1 stigma and increase an individual’s control over their own infection”
-Peter Svensson, CEO
Market potential
For HIV-1 alone, from a research/drug development perspecitve the TAM is estimated 1M€/year, from a diagnostic perspective 15B€/year.
Competitive advantages
Sensitive, cost-effective and applicable to routine samples. Study participants do not need to visit clinic but can measure reservoir from home.
Current Status
First patient materials have been analyzed and is being used to optimize the method. First external users (key opinion leaders) are in line to use product after peer-reviewed publication. Funding for initiation of validation study secured through Vinnova.
Partnerships/
Investments or collaborations sought
We are looking to expand our networkand build long-term relations as to accelerate product development and reduce time to market.
Competition
Competing solutions (MIPseq, PRIPseq) can only be used for research and production is not scalable. For routine diagnostics, PCRs and NGS sequencing capture some of the aspects of our solution but not the most important ones, such as reactivation potential of intact HIV.
IPR
Our underlying CADseq technology is in the process of being patented. Freedom to operate and innovation height has been assessed. Our team also has extensive experience and scientific networks.
